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Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Benign 
adenomas originate from the epithelial cells of the colon and progress to malignancies through the 
accumulation of genetic and epigenetic changes. Studies in cell lines have determined that some 
genetic changes individually alter intracellular signaling pathways that can contribute to cell 
proliferation, survival, and genetic instability. However, the interplay of multiple genetically altered 
signaling pathways is a more important factor driving tumor initiation and progression in vivo, yet 
these interactions remain ill-defined. Indeed, novel therapeutic targets can be uncovered by 
understanding these mechanisms. In a recent paper published in Oncogene, senior author Dr. 
William Grady of the Clinical Research Division reports that alterations of two key oncogenic 
signaling pathways mutated in human colon cancers cooperate to induce colon cancer in an in 
vivo mouse model. 
Colorectal cancers are classified into three subsets based on their type of genomic instability. About 
15% of all colon cancers are of the microsatellite instability (MSI) subtype, which results from defects 
in DNA mismatch repair machinery causing the expansion or contraction of DNA repeats throughout 
the genome. A new in vivo mouse model created in the Grady laboratory recapitulates central 
molecular features found in the MSI class of colorectal cancers. According to Dr. Grady, "this model 
has the potential for use as a preclinical model for colorectal cancer for testing novel therapeutic 
agents." 
Several oncogenic signaling pathways are disrupted in colorectal cancers through genetic 
alterations. In most cases of colon cancer, tumor formation is initiated by mutations that activate the 
Wnt signaling pathway. Additional genetic changes then promote tumor cell growth and survival by 
activating the mitogen activated protein kinase (MAPK) pathway and/or the phosphoinositide-3-
kinase (PI3K)-AKT pathway. The MSI type of colorectal cancer is more dependent on the PI3K-AKT 
pathway, as evidenced by its susceptibility to PI3K inhibitors. Phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) is a negative regulator of the PI3K-AKT pathway, and loss of 
the PTEN gene occurs in 20-40% colorectal cancers, with a high frequency in the MSI class of 
colorectal cancers. Also co-occurring with high frequency in the MSI subset of colorectal cancers is 
the inactivation if the TGF-β signaling pathway, which acts as a tumor suppressor in the colon. 
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Inactivating mutations of the TGF-β receptor 2 gene, TGFBR2, block the TGF-β signaling pathway in 
colon cancer cells. 
Postdoctoral fellow Dr. Ming Yu and colleagues addressed whether disruption of TGF-β signaling 
and loss of PTEN specifically in the epithelial cells of the intestine cooperated to induce intestinal 
cancer formation in mice. Yu et al. found that genetic deletions of 
either TGFBR2 or PTEN individually had little to no effect on colon tumor formation in mice. 
However, 37 out of 43 mice (86%) developed colon tumors and had significantly shortened median 
survival (P < 0.0001) with deletions of bothTGFBR2 and PTEN.  The tumors were histologically 
characterized as primary adenocarcinomas, and the majority had a mucinous histology, which 
means they secrete mucin proteins (see figure). These lesions occurred in the small intestine, 
cecum, colon, and cecal junctions. Furthermore, 8% of the mice had metastasis of the tumors to 
surrounding tissues, including the pancreas, peritoneal cavity, and liver. These results showed that 
inhibition of TGF-β signaling and loss of PTEN cooperated to induce intestinal cancer in mice. 
To understand the mechanism of tumor formation in these double mutant mice, the activation of 
various signaling pathways was examined. PTEN deletion activated AKT in the normal tissues of 
mice as expected, but the tumors of PTEN and TGFBR2knockout mice had less activated AKT 
compared to the adjacent normal tissue. This suggests that lower PI3K activity may favor cancer 
initiation. PTEN is thought to have other functions in the cell, which could also contribute to tumor 
formation. Surprisingly, the Wnt pathway was not activated in the tumors of these mice, suggesting 
tumor initiation occurred independent of this pathway. Some colon cancers do not have Wnt 
pathway mutations, so this mouse model may shed light on the mechanisms involved in tumor 
initiation in those colon cancers that arise through Wnt-independent pathways. The researchers did 
find activation of the MAPK pathway without finding additional mutations, accompanied by increased 
proliferation and decreased apoptosis in the tumor cells. No additional gross chromosomal gains or 
losses were found in these tumors that would indicate additional genetic events that contributed to 
tumor formation. 
Normal TGF-β signaling induces the expression of cyclin dependent kinase (CDK) inhibitors 
p15I
INK4B
, p21
CIP1
, and p27
KIP1
, which negatively regulate the cell cycle and proliferation. Expression 
of all three CDK inhibitors was decreased in tumor versus normal tissue. PTEN and TGFBR2 re-
expression in cells synergized to increased activity of the p21 promoter, proving direct regulation of 
these inhibitors by the two pathways. "These findings raise the possibility that agents that target the 
cyclin–CDK enzyme complexes, which are currently in early phase clinical studies, may be 
particularly effective in colorectal cancers that carry TGFBR2 mutations and lack PTEN expression," 
according to Dr. Grady. 
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 Importantly, the majority of the double mutant mice displayed only one or two intestinal tumors, 
suggesting that additional cooperating events have occurred in the tumor tissue and are involved in 
initiating tumor formation. Future studies will address if additional mechanisms are involved in 
promoting tumor formation in this mouse model. 
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Image provided by Ming Yu and William Grady. 
An H&E stained section of an intestinal adenocarcinoma 
(center mass) from a mouse deficient for TGF-beta receptor 
2 and PTEN. Note the malignant cells penetrating into the 
serous membrane surrounding the intestine and tumor-
specific mucin production (20x magnification). 
 
